HRS-1780

Phase 3Small molecule

SShandong Suncadia Medicine Co., Ltd.

HRS-1780 is one of 50 small molecule programs targeting Primary Aldosteronism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary AldosteronismActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Primary AldosteronismPhase 2

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 2

HRS-1780

SShandong Suncadia Medicine Co., Ltd.

Phase 3

1 3

Uloric

Takeda

Preclinical

3 4

Glucotrol

Pfizer

Preclinical

1 5

Sovaldi

Gilead

Preclinical

1 6

Vemlidy

Gilead

Preclinical

1 7

Miochol

BBausch Health Americas, Inc.

Preclinical

2 8

Januvia

ZZydus Therapeutics Inc.

Preclinical

1 9

PROCRIT

WWim Janssens

Preclinical

1 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Primary Aldosteronism

NCT07470983

Q2 2030

Phase 3Not yet recruiting

Chronic Kidney Disease

NCT07419828

Clinical

Trials by Indication[1]

Interaction2 trials

Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06344936·28 enrolled

Study on Drug Interaction of HRS-1780 Tablets, Henagliflozin Tablets, Metformin Tablets and HRS-7535 Tablets in Healthy Human

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06495931·24 enrolled

Impaired Renal Function1 trial

Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

Unknown status·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT06039254·27 enrolled

Chronic Kidney Disease1 trial

A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 3·NCT07419828·1,978 enrolled

Primary Aldosteronism1 trial

A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT07470983·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for HRS-1780. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-1780 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-1780. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong Suncadia Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShandong Suncadia Medicine Co., Ltd.

HRS-1780

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Trials by Indication[1]

Interaction2 trials

Impaired Renal Function1 trial

Chronic Kidney Disease1 trial

Primary Aldosteronism1 trial

References

Drug Info

Quick Facts

Related News